multi-antigen peptide-loaded DC1 vaccine

This multi-antigen DC1 vaccine is an investigational autologous cellular immunotherapy designed for the treatment of advanced renal cell carcinoma (RCC). It utilizes type-1 polarized dendritic cells (DC1s), which are known for their superior ability to produce interleukin-12 (IL-12) and prime Th1-type immune responses. These patient-derived dendritic cells are loaded with a cocktail of cytotoxic T-lymphocyte (CTL) epitope peptides derived from five tumor-associated antigens frequently overexpressed in kidney cancer: MAGE-3, MAGE-4, survivin (BIRC5), HER2/neu, and COX-2. Administered subcutaneously, the vaccine aims to induce a broad, multi-targeted immune response against cancer cells, potentially overcoming tumor heterogeneity and antigen escape. It has been primarily studied as an adjuvant therapy following radical resection in patients with stage III or IV renal cell carcinoma.

Other names

multi-antigen peptide-loaded DC1 vaccine-Melanoma-associated antigen 3-Melanoma-associated antigen 4-Baculoviral IAP repeat-containing protein 5-Human epidermal growth factor receptor 2-Cyclooxygenase-2-Dendritic cell therapy-Vaccine-Cell therapy-Subcutaneous-Renal Cell CarcinomaDC1-based multi-antigen vaccineDC-1-based multi-antigen vaccineDC 1-based multi-antigen vaccineMAGE-3/MAGE-4/Survivin/HER2/COX-2 DC1 vaccine